-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Counterpoint: No, It Just Adds Cost and Toxicity?

Program: Spotlight Sessions
Session: Smoldering Myeloma: A Case for Early Intervention?
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research, Patient-reported outcomes
Monday, December 9, 2024, 10:30 AM-11:45 AM

Karthik Ramasamy, MD, PhD

University of Oxford, Oxford, United Kingdom; Oxford Translational Myeloma Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, United Kingdom

Disclosures: Ramasamy: GSK: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Menarini Stemline: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Recordati rare Disease: Consultancy, Speakers Bureau.

OffLabel Disclosure: Lenalidomide Daratumumab Carfilzomib Isatuximab Bortezomib

See more of: Smoldering Myeloma: A Case for Early Intervention?
See more of: Spotlight Sessions
<< Previous Presentation | Next Presentation